Efficacy and Long-Term Outcomes of Eltrombopag Treatment Within 6 Months of Diagnosis in Patients With Steroid Unresponsive or Dependent Immune Thrombocytopenia
Am J Hematol
.
2024 Dec 23.
doi: 10.1002/ajh.27568.
Online ahead of print.
Authors
Huyen Tran
1
2
,
Caroline Dix
1
3
,
Robert Bird
4
,
Sanjeev Chunilal
5
,
Tim Brighton
6
,
John Reynolds
7
,
Simon He
3
,
Christine Mazis
1
,
Andrew Grigg
3
Affiliations
1
Clinical Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.
2
Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
3
Clinical Haematology, Austin Hospital, Melbourne, Victoria, Australia.
4
Clinical Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
5
Clinical Haematology, Monash Health, Melbourne, Victoria, Australia.
6
Haematology, New South Wales Health Pathology Randwick, Prince of Wales Hospital, Sydney, New South Wales, Australia.
7
Clinical Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia.
PMID:
39715073
DOI:
10.1002/ajh.27568
No abstract available
Keywords:
eltrombopag; idiopathic thrombocytopenic purpura; pre‐splenectomy.
Publication types
Letter
Grants and funding
Thrombosis and Haemostasis Society of Australia and New Zealand
Novartis Pharmaceuticals Pty Ltd (Australia)